Biogen BIIB

NAS: BIIB | ISIN: US09062X1037   6/02/2026
201,18 USD (+8,53%)
(+8,53%)   6/02/2026
Grafiek Biogen Inc. Grafiek Biogen Inc.
vrijdag 6 februari 2026, 13:00
Kwartaalcijfers (4de kwartaal)

Biogen Inc. in het nieuws

4 februari 2026 · Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy · Persbericht

28 januari 2026 · Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options · Persbericht

26 januari 2026 · FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review · Persbericht

12 januari 2026 · Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy · Persbericht

22 december 2025 · The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS · Persbericht

5 december 2025 · Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting · Persbericht

4 december 2025 · Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 · Persbericht

2 december 2025 · New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF · Persbericht

25 november 2025 · Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status · Persbericht

24 november 2025 · Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions · Persbericht

Profiel Biogen Inc.

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.biogen.com

Hoofdzetel: Cambridge, Massachusetts vlag Verenigde Staten

Mijn selecties